Mizuho Discusses Biogen (BIIB) Seizure Patient
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
December 8, 2016 6:16 PM ESTData Includes Analyses of Phase 1b Titration Cohort and Long-Term Extension Cohort
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimers disease (AD), today at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.... More
